This is a national multi-center, large sample size case registration clinical study. The registry population was patients with inflammatory skin diseases who were receiving treatment with vunakizumab. All outpatient and inpatient patients with inflammatory skin diseases who were receiving vunakizumab were eligible for enrollment. Patients' usual care was not affected by participation in the study. We only collected data in routine clinical practice. The study had an enrollment period of 5 years or 10,000 patients were recruited early, whichever occurred first. All patients must provide written informed consent form before data collection, and each patient will be followed for 1 year to observe clinical progression.
Study Type
OBSERVATIONAL
Enrollment
10,000
Change from baseline in DLQI scores over 52 weeks
DLQI: Dermatology Life Quality Index, range from 0 to 30, with higher scores indicating greater impact on quality of life
Time frame: Weeks 0 to 52
Change from baseline in BSA over 52 weeks
BSA: body surface area
Time frame: Weeks 0 to 52
Change from baseline in IGA over 52 weeks
IGA: Investigator Global Assessment
Time frame: Weeks 0 to 52
Patterns of administration of vunakizumab for the treatment of different inflammatory skin diseases
The dose, interval, duration, and combined treatment of patients receiving vunakizumab were evaluated
Time frame: Weeks 0 to 52
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.